Examples for such markers/targets, in the case of breast cancer, are the oestrogen receptor (ER), progesterone receptor (PgR), and the Erb2/Her2 molecule, a receptor tyrosine protein kinase that is overexpressed in a subset of breast cancers. There are number of treatment options for tumours that express the ER, PgR or Her2 receptors, however up to 20 percent of the newly diagnosed cases belong to a subset, which is negative for all three of the receptor molecules. This presentation will discuss applications of high-resolution hybrid mass spectrometry for quantitative genome-scale studies of protein abundance and post-translational modifications. The current state-of-the-art technology for large-scale proteome analysis of individual solid tumours is discussed. Case studies from experiments with triple-negative breast and colorectal tumours illustrating the capability of the proteome-based strategies are presented, as well as mechanistic investigations in cultured cells that have been informed by tumour proteomics and focus on specific phosphorylation hotspots and protein interactions of the tumour suppressor Scribble.
Genome-Scale Protein Expression Analysis of Individual Solid Tumors
Video May 12, 2015
The genetic code of all 500,000 UK Biobank volunteer participants will be sequenced by researchers at the Wellcome Sanger Institute in the UK and deCODE genetics in Iceland. This project is the single most ambitious sequencing programme in the world undertaken by a public-private partnership, and will power the next wave of genetic and health researchWATCH NOW